EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparison of Letermovir Versus Ganciclovir for Cytomegalovirus Prophylaxis in Pediatric Hematopoietic Stem Cell Transplant Recipients

Catherine E Martin iD, Mira A Kohorst iD, Asmaa Ferdjallah, Theresa Madigan, Laura M Dinnes, Alexis K Kuhn iD

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31732 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Catherine E Martin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Ganciclovir, Antiviral Agents. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Mayo Clinic Department of Pharmacy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients at high risk for cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplant (HCT) should receive CMV prophylaxis. Historically, ganciclovir has been the preferred agent. However, its side effect profile, particularly myelosuppression, is undesirable. Letermovir is a newer agent that is not myelosuppressive and has replaced ganciclovir as the preferred agent for CMV prophylaxis in high‐risk adult patients.

Methods

The primary objective was to compare the incidence of dose modifications or discontinuation of CMV prophylaxis between pediatric patients who received ganciclovir versus letermovir. Secondary objectives included comparing the use of granulocyte colony‐stimulating factor (G‐CSF) support and the incidence of CMV DNAemia. We reviewed records of all pediatric patients who received an HCT at our institution between 2000 and 2024 and received either ganciclovir/valganciclovir or letermovir for CMV prophylaxis.

Results

Between 2000 and 2024, 65 pediatric patients receiving prophylactic ganciclovir, valganciclovir, or letermovir were evaluated. The median age at transplant was 12.2 years. No patients receiving letermovir required dose modification or discontinuation as opposed to 14 (29.2%) patients receiving ganciclovir ( p = 0.014). After engraftment, 12 (25%) patients receiving ganciclovir required G‐CSF support compared to seven (41.2%) patients receiving letermovir ( p = 0.23). In the ganciclovir group, 10 (20.8%) patients experienced CMV infection versus one (5.9%) patient receiving letermovir ( p = 0.26).

Conclusion

Compared with those receiving letermovir, a significantly higher proportion of patients in the ganciclovir/valganciclovir group experienced dose modifications or discontinuation of CMV prophylaxis due to adverse effects. Letermovir shows great promise as a CMV prophylactic agent in pediatric HCT patients due to its favorable side effect profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsHematopoietic Stem Cell TransplantationGanciclovirAntiviral AgentsAcetatesCytomegalovirusQuinazolinesHumansFemaleChildMaleAdolescentChild, PreschoolRetrospective StudiesFollow-Up StudiesInfantPrognosis

Stichwörter der Autor:innen

anti‐viral prophylaxiscytomegalovirusganciclovirletermovir

Substanzen

letermovirGanciclovirAntiviral AgentsAcetatesQuinazolines

Autor:innen und Institutionen

  • Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Pediatric Hematology/Oncology, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Pediatric Infectious Diseases, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Catherine E Martin, Mira A Kohorst, Alexis K Kuhn

Förderung

  • Mayo Clinic Department of Pharmacy

Zitieren

APA

Martin, C. E., Kohorst, M. A., Ferdjallah, A., Madigan, T., Dinnes, L. M., & Kuhn, A. K. (2025). Comparison of Letermovir Versus Ganciclovir for Cytomegalovirus Prophylaxis in Pediatric Hematopoietic Stem Cell Transplant Recipients. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31732

Vancouver

Martin CE, Kohorst MA, Ferdjallah A, Madigan T, Dinnes LM, Kuhn AK. Comparison of Letermovir Versus Ganciclovir for Cytomegalovirus Prophylaxis in Pediatric Hematopoietic Stem Cell Transplant Recipients. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31732

BibTeX
@article{Martin2025,
  author = {Martin, Catherine E and Kohorst, Mira A and Ferdjallah, Asmaa and Madigan, Theresa and Dinnes, Laura M and Kuhn, Alexis K},
  title = {Comparison of Letermovir Versus Ganciclovir for Cytomegalovirus Prophylaxis in Pediatric Hematopoietic Stem Cell Transplant Recipients},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31732}
}
Kostenlos starten →